Literature DB >> 29743354

Inhibitory Effects of HIV-2 Vpx on Replication of HIV-1.

Mohamed Mahdi1, Zsófia Szojka2, János András Mótyán2, József Tőzsér1.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) and HIV-2 share a striking genomic resemblance; however, variability in the genetic sequence accounts for the presence of unique accessory genes, such as the viral protein X (vpx) gene in HIV-2. Dual infection with both viruses has long been described in the literature, yet the molecular mechanism of how dually infected patients tend to do better than those who are monoinfected with HIV-1 has not yet been explored. We hypothesized that in addition to extracellular mechanisms, an HIV-2 accessory gene is the culprit, and interference at the viral accessory/regulatory protein level is perhaps responsible for the attenuated pathogenicity of HIV-1 observed in dually infected patients. Following simulation of dual infection in cell culture experiments, we found that pretransduction of cells with HIV-2 significantly protects against HIV-1 transduction. Importantly, we have found that this dampening of the infectivity of HIV-1 was a result of interviral interference carried out by viral protein X of HIV-2, resulting in a severe hindrance to the replication dynamics of HIV-1, influencing both its early and late phases of the viral life cycle. Our findings shed light on potential intracellular interactions between the two viruses and broaden our understanding of the observed clinical spectrum in dually infected patients, highlighting HIV-2 Vpx as a potential candidate worth exploring in the fight against HIV-1.IMPORTANCE Dual infection with human immunodeficiency virus types 1 and 2 is relatively common in areas of endemicity. For as-yet-unclarified reasons, patients who are dually infected were shown to have lower viral loads and generally a lower rate of progression to AIDS than those who are monoinfected. We aimed to explore dual infection in cell culture, to elucidate possible mechanisms by which HIV-2 may be able to exert such an effect. Our results indicate that on the cellular level, pretransduction of cells with HIV-2 significantly protects against HIV-1 transduction, which was found to be a result of interviral interference carried out by viral protein X of HIV-2. These findings broaden our knowledge of interviral interactions on the cellular level and may provide an explanation for the decreased pathogenicity of HIV-1 in dually infected patients, highlighting HIV-2 Vpx as a potential candidate worth exploring in the fight against HIV.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; HIV-2; Vpx; dual infection; dual transduction; viral infectivity

Mesh:

Substances:

Year:  2018        PMID: 29743354      PMCID: PMC6026746          DOI: 10.1128/JVI.00554-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

Review 1.  Infection with HIV-2.

Authors:  P J Bock; D M Markovitz
Journal:  AIDS       Date:  2001       Impact factor: 4.177

2.  A HIV-2-based self-inactivating vector for enhanced gene transduction.

Authors:  Sayandip Mukherjee; Hui-Ling Rose Lee; Annmarie L Pacchia; Yacov Ron; Joseph P Dougherty
Journal:  J Biotechnol       Date:  2006-09-18       Impact factor: 3.307

3.  Expression and purification of soluble HIV-2 viral protein R (Vpr) using a sandwich-fusion protein strategy.

Authors:  Karen Hänel; Luis Möckel; Monika Brummel; Katja Peiris; Rudolf Hartmann; Andrew J Dingley; Dieter Willbold; Angelika Loidl-Stahlhofen
Journal:  Protein Expr Purif       Date:  2013-12-29       Impact factor: 1.650

4.  Population mobility and the changing epidemics of HIV-2 in Portugal.

Authors:  A C Carvalho; E Valadas; L França; C Carvalho; M J Aleixo; J Mendez; R Marques; A Sarmento; M Doroana; F Antunes; T Branco; M Aguas; R Sarmento E Castro; J V Lazarus; H Barros
Journal:  HIV Med       Date:  2011-12-04       Impact factor: 3.180

5.  Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades.

Authors:  A Bertoletti; F Cham; S McAdam; T Rostron; S Rowland-Jones; S Sabally; T Corrah; K Ariyoshi; H Whittle
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

6.  Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.

Authors:  Adam MacNeil; Abdoulaye Dieng Sarr; Jean-Louis Sankalé; Seema Thakore Meloni; Souleymane Mboup; Phyllis Kanki
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

7.  Dual infection with human immunodeficiency virus type 1 and type 2: impact on HIV type 1 viral load and immune activation markers in HIV-seropositive female sex workers in Abidjan, Ivory Coast.

Authors:  J N Nkengasong; L Kestens; P D Ghys; S Koblavi-Dème; R A Otten; C Bilé; C Maurice; M Kalou; M Laga; S Z Wiktor; A E Greenberg
Journal:  AIDS Res Hum Retroviruses       Date:  2000-09-20       Impact factor: 2.205

8.  Identification of the nuclear localization signal of human immunodeficiency virus type 2 Vpx.

Authors:  Michael Belshan; Lee Ratner
Journal:  Virology       Date:  2003-06-20       Impact factor: 3.616

9.  Novel macromolecular inhibitors of human immunodeficiency virus-1 protease.

Authors:  Gabriella Miklóssy; József Tözsér; János Kádas; Rieko Ishima; John M Louis; Péter Bagossi
Journal:  Protein Eng Des Sel       Date:  2008-05-13       Impact factor: 1.650

Review 10.  Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis.

Authors:  Samuel Nyamweya; Andrea Hegedus; Assan Jaye; Sarah Rowland-Jones; Katie L Flanagan; Derek C Macallan
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

View more
  1 in total

1.  Y44A Mutation in the Acidic Domain of HIV-2 Tat Impairs Viral Reverse Transcription and LTR-Transactivation.

Authors:  Zsófia Szojka; János András Mótyán; Márió Miczi; Mohamed Mahdi; József Tőzsér
Journal:  Int J Mol Sci       Date:  2020-08-17       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.